The prophylactic efficacy of ofloxacin (OFLX) therapy was evaluated in 51 granulocytopenic episodes in 22 patients with hematological malignancies during post-remission chemotherapy in a prospective, randomized, controlled trial. Oral administration of OFLX plus amphotericin-B (AMPH) and polymyxin-B (PL) reduced episodes of fever and infection more than did the control regimen with PL and AMPH alone (p < 0.01), and the reduction in the incidence of infection was evident even in patients showing severe granulocytopenia (p < 0.01). Furthermore, the first fever after the onset of granulocytopenia in the OFLX regimen developed later than that in the control regimen (p < 0.05). Clinically, the prophylactic efficacy was 92% for the OFLX regimen and 40% for the control regimen (p < 0.01). These findings suggest that OFLX is a promising prophylactic agent following post-remission chemotherapy. Patient hemomyelo gram findings similar to those of patients with other malignancies may imply that OFLX is widely effective in granulocytopenic patients taking aggressive chemotherapy. (Internal Medicine 31: 319-324, 1992) 
Introduction
Advances in the treatment of patients with hematological malignancies have brought about substantial improvement in their outcome in the last couple of decades (1, 2) . However, the treatment often leads to the infections that frequently occur during intensive anticancer therapy (3) . Especially in patients in remission, the infections accompanying the granulocytopenia induced by sequential chemotherapy may be a greater problem than the underlying hematological malignancies themselves. This propensity has necessitated the development of a prophylactic regimen to protect patients from serious infections and to facilitate safe completion of the entire post-remission chemotherapy schedule. Several controlled trials have shown that prophylactic use of oral nonabsorbable antimicrobial agents (4, 5) and trimethoprim-sulfamethoxazole (6, 7) decreases the incidence of infection but can be associated with gastrointestinal irritability, poor patient compliance, prolonged periods of granulocytopenia, high incidence of fungus colonization and superinfections, and the selection of resistant gram-negative organisms. Recently, fluoroquinolones were found to be safe and effective in patients with hematological malignancies (8) (9) (10) (11) (12) (13) (14) (15) . However, in previous trials using fluoroquino lones, the efficacy of prophylactic agents in granulocy topenic patients may have been obscured, because the immunocompromised state is induced not only by granu locytopenia but also by underlying malignancies. Of fluoroquinolones, ofloxacin (OFLX) possesses a wide spectrum of activity, and is more potent in vitro than other fluoroquinolones, such as norfloxacin and cipro floxacin (16, 17) . Oral administration of OFLX not only preserves the anaerobic flora of the gastrointestinal (GI) tract but also produces a serum level sufficient to be effective in sites outside the GI tract, such as the respir atory tract and blood (18) . For these reasons, we con ducted a prospective, randomized, controlled trial of the prophylactic use of oral OFLX in granulocytopenic patients during post-remission chemotherapy for hemato logical malignancies. N Department of Internal Medicine, Fukui Red-Cross
Patients and Methods

Patien ts
We examined all patients admitted to the Fukui Medical School Hospital or Fukui Red Cross Hospital from August 1989 to June 1990 who were diagnosed as having acute leukemia, malignant lymphoma, or multiple myeloma with a normal neutrophil count before con ducting intensive combination chemotherapy with anti cancer drugs. Patients with acute leukemia who did not achieve complete remission and patients with malignant lymphoma or multiple myeloma who did not show com plete or partial response to prior therapy were excluded from this study. Remission and response to therapy were judged according to Kimura's criteria for acute leukemia (19) and malignant lymphoma (20) , or Imamura's criteria for multiple myeloma (21) . All patients participating in the study gave informed consent. Study design Patients entered the study when leukopenia (<1,000/ /il) or granulocytopenia (<500//il) developed after the combination chemotherapy. At that time, all patients were randomly classified into the following two groups: 1) the controls who received 3 x 106 units of polymyxin B (PL) and 600mg of amphotericin-B (AMPH) orally to decontaminate the GI tract (control group); and 2) those who received 600mg of OFLX as well as AMPH and PL orally as general prophylaxis as well as to decontaminate the GI tract (OFLX group). Administration of these drugs was maintained until a high fever (>38.0°C) per sisted for three days or until the leukocyte count re covered to more than l,500//il. At the first onset of fever ascribed to infection associated with granulocytopenia, specimens of blood, pharyngeal swab or sputum, stool and urine were collected, and cultured. Additional bacteria and fungi were isolated from each infected site by culturing the specimens. Serologic tests and chest X-rays were performed if necessary. Some antibiotics were used empirically in addition to OFLX.
Evaluation of granulocytopenia, infection and prophylaxis
Granulocytopenia was identified when the neutrophil count became less than 500//d, and the severity of granulocytopenia was classified according to the mini mum neutrophil count during the course of the study as moderate (50-500/^1) or severe (0-50//i). The febrile episodes were categorized into the following groups: 1) documented infection (indentification of the infected site and/or isolation of the organism from the infected site); 2) probable infection (infection suspected in a febrile patient with no organism identified) ; 3) doubtful infection (a febrile episode caused by anything other than in fection, such as blood products, drugs or cancer). Clinical infectious state was considered to include documented and probable infection. Prophylactic efficacy was clini cally evaluated by the following criteria: 1) excellent:
no fever during episode of severe granulocytopenia; 2) good: no fever during episode of moderate granulocyto penia; 3) fair: fever of short duration (less than 3 days) during severe granulocytopenia; 4) poor: prolonged fever or documented infection; and 5) non-evaluable: protocol violation. Statistical analysis Differences between medians were analyzed by unpaired t test (i), and differences between groups were analyzed by the chi-square test (x2) or Fisher's exact test (F) . Results
Patient characteristics
Prophylaxis was administrated for a total of 51 granu locytopenic episodes in 22 patients. There were 25 episodes in the OFLX group plus one episode in which fever developed before the administration of OFLX, and 25 episodes in the control group. Tolerance and com pliance on both OFLX and control regimens during the study period were excellent. Drug intolerance mani festing as nausea was observed in only one patient in the OFLX group and in none in the control group. Additionally, neither hypersensitivity nor other un expected side effects which could be attributed to OFLX was observed. The characteristics of the 50 episodes of granulocytopenia evaluated in this study are sum marized in Table 1 . There was no significant difference r The total number of episodes through complete culture of specimens such as blood, sputum or paharyngeal swab, urine and stool at the onset of fever, and the total number of episodes with infections (parenthesis). The number of positive specimen isolated from a) sputum or pharyngeal swab, b) urine and c) stool. * Fisher's exact test, p< 0.05.
between the two groups in underlying disease, age, or sex. Chemotherapy regimens, which varied due to underlying disease and patient condition, induced severe and prolonged granulocytopenia to the same degree in both the OFLX group and the control group. In addition, patients in both groups with acute nonlymphocytic leukemia (ANLL) showed more severe and prolonged granulocytopenia than those with other hematological malignancies.
Types offebrile episodes The types of febrile episode are summarized in Table 2 .
There was one episode of clinically documented in fection diagnosed as pneumonia in the control group, and one episode of doubtful infection considered to be due to blood products in the OFLX group. Other episodes were diagnosed as probable infection. The total number of episodes of infection diagnosed as documented or probable infection in the OFLX group was less than that in the control group (#2, p <0.01).
" Percent incidence in parenthesis : Fisher's exact test, p< 0.01 * Unpaired t test, p<0.05
Culture study Complete culture study of specimens including blood, sputum or pharyngeal swab, urine and stool was per formed in 19 of 27 febrile episodes (7 in the OFLX group, and 12 in the control group) when fever devel oped. Organisms isolated are listed in Table 3 . Gram positive bacilli were more often isolated in the OFLX group than in the control group, but this difference was not statistically significant. It should be noted that Candida species (sp) from pharyngeal swabs or sputum were more often isolated in the OFLX group than in the control group (F, p < 0.05). No Staphylococcus sp mul tiply resistant to more than two antimicrobial agents was observed.
Granulocytopenia and infections
The relationship between granulocytopenia and the occurrence of infection is summarized in Table 4 . In control patients, severe granulocytopenia manifested infection during febrile episode more frequently than moderate granulocytopenia (F, p < 0.05). In contrast, there was no significant relationship between the severity of granulocytopenia and the incidence of infection in the OFLX patients, and the OFLX regimen reduced the incidence of the infection even in the patients showing severe granulocytopenia compared to that in the control patients (F, p<0.01). Furthermore, with respect to febrile episodes associated with infection after the onset of granulocytopenia, the first fever developed later in the OFLX group that it did in the control group (t, p < 0.05).
Clinical prophylactic efficacy compared to that in patients of the control group (x2, p<0.01).
Discussion
Previous trials with fluoroquinolones in patients with hematological malignancies have demonstrated pro phylactic efficacy by minimal incidence of documented infection and isolation of gram-negative organisms (8) (9) (10) (11) (12) (13) (14) (15) . However, in these trials, the greater incidence of febrile episodes than that of documented infection (10, 15) may obscure the efficacy of fluoroquinolones against infection induced by granulocytopenia. Causative organisms are less freqnently isolated in frebrile patients with hematological malignancies than in those with other disorders (10, 15) , and many febrile episodes without isolation of causative organisms are considered to be infection due to septicemia (3, 22) . In the present study, OFLX administration brought about a decreased in cidence of febrile episodes, rather than documented infection. Furthermore, this prophylactic efficacy was evident even in patients with severe granulocytopenia. Since the immunocompromised state brought by under lying disease may affect the occurrence of infection, the findings in the present study conducted in patients during post-remission chemotherapy should be more accurate in prophylactic efficacy in patients with granulocytopenia than in those of previous fluoroquinolone studies which included patients in deteriorated condition due to under lying disease. The results in the present study suggest that use of OFLX is satisfactory in preventing febrile episodes, with clinical prophylactic efficacy observed in more than 90% (Fig. 1) .
The efficacy of OFLX in preventing infections may be greater than that of nonabsorbable antimicrobial agents which include a fluoroquinolone, such as norfloxacin (23) . The fact that OFLX is superior to other nonabsorb able agents in preventing infection is thought to be related to its potent microbial activity in vitro (16) and production of a greater drug concentration in serum (18) , lung tissue (24) and saliva (13) than other nonabsorbable fluoro quinolones. Several nonabsorbable antimicrobial agents, such as aminoglycoside (4, 5) , polymyxin or vancomycin, and norfloxacin (8-10, 14, 15) were used for decontami nation of the GI tract, a major route for the causative organisms (25) . However, many of the gram-positive infections in granulocytopenic patients arose from central intravenous catheters or other sites outside the GI tract (14, 26) . Thus, the higher concentration of OFLX in serum may improve its effectiveness for the prevention of infections outside the GI tract in granulocytopenic patients. In addition, fluoroquinolones offer the advant age of being absorbable by granulocytes (27); this pro perty may be particularly useful in killing phagocytosed bacteria in granulocytes which are functionally abnormal due to primary disease or to drug side effect. increase (28). The emergence of fluoroquinolone-re sistant organisms has not been a major problem in pre vious prophylactic studies (14) , and in the present study treatment with OFLX resulted in a decrease in the detection of gram-positive organisms such as S. epidermidis. Furthermore, fluoroquinolones does not predispose to the emergence of organisms resistant to the major systemic antibiotics or to complicate treatment of documented infections caused by fluoroquinolone resistant organisms, because fluoroquinolone has action mechanisms different from those of major systemic antibiotics (29). However, the Candida sp which was observed more frequently in the OFLX group is pre sumed to reflect opportunistic pathogetic infection arising during persistent treatment with OFLX, suggesting that more effective prophylaxis against fungus infections and the like is needed. Finally, further benefits of OFLX prophylaxis lie in its potential to improve the quality of the patient's life and to lower the overall cost of medical care incurred as a result of infections during prolonged marrow aplasia.
Since in the present study the patients selected had normal hemomyelograms similar to those in patients taking chemotherapy due to other malignancies, the prophylaxis due to OFLX in granulocytopenic patients may be promising not only in those with hematological malignancies but also in those with other malignancies. However, continuous monitoring for the emergence of drug resistance is required especially if OFLX becomes more widely used for prophylaxis, and particularly in patients showing prolonged granulocytopenia and con sequent prolonged use of OFLX.
